Table 1.
Protein expression changes induced by TGF-β (24 hour treatment) in BRI-JM01 cells, identified by WGA affinity workflow.
| BR1 | BR2 | BR3 | ||||
| Swiss-Prot | # pept | ratio1 ± SD | # pept | ratio ± SD | # pept | ratio ± SD |
| UP-REGULATED | ||||||
| Q06890|CLUS_MOUSE Clusterin precursor | ||||||
| 9 | 4.21 ± 0.51 | 7 | 4.26 ± 0.17 | 3 | 4.25 ± 0.45 | |
| P11276|FINC_MOUSE Fibronectin precursor (FN) | ||||||
| 7 | 1.85 ± 0.37 | 8 | 1.63 ± 0.69 | 3 | 1.92 ± 0.57 | |
| P11688|ITA5_MOUSE Integrin alpha-5 | ||||||
| 2 | 1.41 ± 0.21 | 2 | 1.97 ± 0.16 | 1 | 9.93 ± 1.33 | |
| NP_997551.1| Acid phosphatase, prostate isoform 1 [NP_062781.2] | ||||||
| 1 | 1.40 ± 0.17 | 1 | 1.49 ± 0.21 | 0 | -- | |
| O70309|ITB5_MOUSE Integrin beta-5 | ||||||
| 2 | 1.39 ± 0.14 | 2 | 0.99 ± 0.16 | 2 | 1.55 ± 0.10 | |
| NP_058085.1| Heterogeneous nuclear ribonucleoprotein U | ||||||
| 2 | 1.36 ± 0.6 | 2 | 1.37 ± 0.27 | 0 | -- | |
| P63260|ACTG_MOUSE Actin, cytoplasmic 2 [P60710] | ||||||
| 8 | 1.34 ± 0.21 | 10 | 1.13 ± 0.08 | 6 | 1.62 ± 0.08 | |
| DOWN-REGULATED | ||||||
| Q9QZM0|UBQL2_MOUSE Ubiquilin-2 | ||||||
| 1 | 0.91 ± 0.71 | 3 | 0.69 ± 0.08 | 1 | 0.64 ± 0.16 | |
| Q8R143|PTTG_MOUSE Pituitary tumor-transforming gene 1 | ||||||
| 2 | 0.80 ± 0.05 | 2 | 0.70 ± 0.04 | 0 | -- | |
| P35951|LDLR_MOUSE Low-density lipoprotein receptor precursor | ||||||
| 1 | 0.62 ± 0.11 | 1 | 0.71 ± 0.06 | 0 | -- | |
| Q61739|ITA6_MOUSE Integrin alpha-6 | ||||||
| 13 | 0.57 ± 0.08 | 13 | 0.79 ± 0.04 | 4 | 0.87 ± 0.03 | |
| NP_598424.2| Integrin beta 4 | ||||||
| 15 | 0.56 ± 0.08 | 15 | 0.84 ± 0.05 | 3 | 0.98 ± 0.22 | |
| NP_064431.2| tumor-associated calcium signal transducer 2 | ||||||
| 2 | 0.51 ± 0.12 | 2 | 0.57 ± 0.05 | 0 | -- | |
1abundance in TGF-β/abundance in CTL